Andrew Komjathy has been appointed chief commercial officer of Catabasis Pharmaceuticals (NASDAQ: CATB). He joins the Cambridge, MA, drug developer from Alkermes (NASDAQ: ALKS), where he was vice president of commercial sales. His experience also includes positions at Genzyme, Shire, and Biogen (NASDAQ: BIIB). Catabasis has changed its therapeutic focus several times
, having pursued drugs for diabetes and high cholesterol among other diseases. Its most advanced compound, edasalonexent, is in Phase 3 testing in Duchenne muscular dystrophy.
Sponsored · Whitepaper
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research
Brex
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
Sponsored · Whitepaper
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace
